JCR Pharmaceuticals Co., Ltd.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Toru Ashida
- Full Time Employees
- 985
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 3-19 Kasuga-cho Ashiya HY Japan 659-0021
- IPO Date
- Mar 16, 1995
- Website
- jcrpharm.co.jp
- Similar Companies
- Business
- JCR Pharmaceuticals Co., Ltd. is a Japanese specialty biopharmaceutical company engaged in the research, development, manufacturing, import, export, and sale of pharmaceutical products, regenerative medicines, and drug substances. Its product portfolio includes therapeutic products for growth hormone deficiency and short stature under the GROWJECT brand; treatments for lysosomal storage diseases such as IZCARGO for Mucopolysaccharidosis type II and Agalsidase Beta BS I.V. Infusion for Fabry disease; regenerative medical products like TEMCELL HS Inj. for acute graft-versus-host disease; and renal anemia therapies including Epoetin Alfa BS Injection JCR and Darbepoetin Alfa BS Injection JCR. JCR also sells medical devices, laboratory instruments, and medical and research equipment primarily in Japan and internationally. Founded in 1975, the company is headquartered in Ashiya, Japan. Recent major developments include the establishment of a Japan Development Unit in October 2025 aimed at accelerating strategic drug development in the domestic market and responding to evolving regulatory conditions. The company also reorganized its Quality Assurance Division by integrating quality management functions and creating three new departments to support unified quality management policies. Additionally, the Research Division was realigned to enhance collaboration across Chemistry, Manufacturing, and Control (CMC) functions in preparation for global regulatory submissions. JCR has active collaboration agreements, including one with Angelini Pharma for novel biologic therapies and a joint research agreement with Modalis Therapeutics Corporation to evaluate gene therapy drug delivery technologies targeting central nervous system diseases. In 2024, JCR regained full commercialization rights to the drug JR-141 (pabinafusp alfa) used in treating mucopolysaccharidosis II, consolidating its market position in rare diseases. JCR Pharmaceuticals operates in segments focused on rare genetic diseases, regenerative medicine, renal anemia, and specialized medical equipment, targeting hospitals, specialty clinics, and research institutions globally. The company continues to emphasize innovation through biopharmaceutical research and maintains a strategic focus on expanding its pipeline for rare and central nervous system disorders. Its recent organizational and strategic realignments position it for enhanced product development, quality assurance, and market responsiveness in the rapidly evolving pharmaceutical landscape.
Company News
JCR Pharmaceuticals Receives Marketing Authorization in Kuwait for IZCARGO™, a Blood-Brain Barrier-Penetrating Enzyme Replacement Therapy for Hunter Syndrome
Italfarmaco and JCR Pharmaceuticals Enter into Exclusive License Agreement for the Development and Potential Commercialization of Novel Investigational Therapy for Hunter Syndrome in the United States, Europe, and Latin America
JCR Pharmaceuticals Receives Orphan Drug Designation from the Ministry of Health, Labour and Welfare of Japan for Givinostat for Duchenne Muscular Dystrophy
MEDIPAL HOLDINGS CORPORATION and JCR Pharmaceuticals Dose First Patient in Global Phase I/II Trial of JR-446 for Mucopolysaccharidosis Type IIIB
JCR Pharmaceuticals Receives Marketing Authorization in the United Arab Emirates for IZCARGO™, a Blood-Brain Barrier-Penetrating Enzyme Replacement Therapy for Hunter Syndrome
JCR Pharmaceuticals Announces That Acumen Pharmaceuticals Has Exercised its Exclusive Option to Develop Therapeutic Candidates for Alzheimer's Disease, Enabled by J-Brain Cargo® Technology Platform
JCR Pharmaceuticals' Research Presentations at the 18th International Symposium on MPS and Related Lysosomal Diseases 2026 Showcase Data from Its Investigational Treatments for Lysosomal Storage Disorders
JCR Pharmaceuticals to Present at the 18th International Symposium on MPS and Related Lysosomal Diseases 2026
JCR Pharmaceuticals Presents Preclinical Gene Therapy Data that Demonstrate Promising Central Nervous System Uptake at the American Society of Gene and Cell Therapy (ASGCT) 29th Annual Meeting
JCR Pharmaceuticals to Present at the American Society of Gene and Cell Therapy (ASGCT) 29th Annual Meeting
JCR Pharmaceuticals' Research Presentations at WORLDSymposium™ 2026 Showcase Data from Its Investigational Treatments for Lysosomal Storage Disorders
JCR Pharmaceuticals to Present at the 22nd Annual WORLDSymposium™ 2026
JCR Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
Italfarmaco and JCR Pharmaceuticals Announce Commercialisation Agreement for Givinostat in Japan and Strategic Collaboration in Rare Disease
JCR Pharmaceuticals Co., Ltd. (OTCMKTS:JCRRF) Short Interest Update
JCR Pharmaceuticals Enhances Delivery of AAV Gene Therapy to Central Nervous System and Muscle with Novel Capsid Engineering Platform Technology
JCR Pharmaceuticals Announces Licensing Agreement with Menagen to Commercialize Agalsidase Beta BS I.V. Infusion [JCR] Across Nine MENAT Markets
JCR Pharmaceuticals to Present at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress
JCR Pharmaceuticals and Alexion Achieve Milestone in Collaborative Neurodegenerative Disease Program
JCR Pharmaceuticals Celebrates its 50th Anniversary of Advancing Science and Changing Lives